Using gene enrichment analyses from type 2 diabetes and cancer GWAS studies, network analyses and literature mining, the authors identified seven enriched genes (PPARGC1A, CDKN1A, MYC, ESR1, MAX, STK11, and SP1) impinging on a novel Myc-associated pathway that they proposed played a key role in metformin’s anti-cancer MOA. This evidence concerns the gene MYC and type 2 diabetes mellitus.